IPOpulse
Back to Ticker

Poly Medicure Limited

NSE: POLYMED
Healthcare Healthcare
₹1,550.7
-2.70%EOD · 19 Oct

Poly Medicure Limited is a listed Healthcare company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap
₹15,718 Cr
52W Range
₹2094 / ₹1182
Volume
56K
44.0% delivery
1Y Return
-18.2%
P/E Ratio
51.3
P/B Ratio
5.2
ROE
10.8%
Debt / Equity
11.23

Peers in Healthcare

Top 8 by market cap
CompanyLTP30DMarket CapP/EP/BROE %Div Yld %
Poly Medicure Limited(this stock)₹1,550.7₹15,718 Cr51.35.210.8%0.22%
Divi's Laboratories LimitedDIVISLAB₹9,087₹2.41 L Cr83.014.516.2%0.33%
Torrent Pharmaceuticals LimitedTORNTPHARM₹4,558.7₹1.73 L Cr72.818.417.0%0.83%
Laurus Labs LimitedLAURUSLABS₹2,069₹1.12 L Cr101.821.017.7%0.12%
Zydus Lifesciences LimitedZYDUSLIFE₹1,113.9₹1.11 L Cr25.04.218.3%0.09%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP₹7,700₹1.11 L Cr54.312.021.5%0.25%
Aurobindo Pharma LimitedAUROPHARMA₹1,621.4₹93,292 Cr26.12.69.9%0.00%
Mankind Pharma LimitedMANKIND₹2,253.2₹93,067 Cr46.05.812.4%0.00%
Max Healthcare Institute LimitedMAXHEALTH₹830₹80,785 Cr56.77.714.3%0.23%

Quality Score

Durability · Valuation · Momentum — objective math, not advice
D
29/100
Composite score: 40% quality, 30% valuation, 30% momentum
QualityAverage · 43
ValuationWeak · 30
MomentumPoor · 10
High debt load (D/E 11.2)
In confirmed downtrend (Stage 4)

Technical Indicators

Full analysis · objective math, not advice
Returns
1D
-2.7%
1W
-5.5%
1M
-9.5%
3M
-9.9%
6M
+5.7%
1Y
-18.2%
Weinstein Stage
Stage 4 — Declining (downtrend)
RSI (14)
36 Neutral
Trend Template
3/7weak
RS vs Nifty (3M)
-4.1pp
Moving Averages (price vs MA)
20-DMA
₹1639
below
50-DMA
₹1705
below
150-DMA
₹1580
below
200-DMA
₹1561
below
From 52W High
-26.0%
From 52W Low
+31.2%
Support (20D)
₹1543
Resistance (20D)
₹1772

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Community discussion(0)

Sign in to join the discussion.

Sign in

No comments yet — be the first to share your view.